Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jpn J Clin Oncol. 2010 Jul;40(7):694-8. doi: 10.1093/jjco/hyq039. Epub 2010 Apr 28.
To date, only seven women with Stage Ib1 to IIb cervical cancer during pregnancy treated with neoadjuvant chemotherapy followed by radical surgery have been reported. We describe three cases of pregnant women with Stage Ib1 to IIa cervical cancer who were treated with paclitaxel plus platinum neoadjuvant chemotherapy followed by radical surgery. The first patient had a Stage Ib1 small cell neuroendocrine carcinoma of the cervix, the second had a Stage IIa, 8 cm squamous cell carcinoma of the cervix and the third had a Stage Ib2 squamous cell carcinoma and positive lymph nodes. The three patients and their newborns were followed up. All patients had a partial or complete response to neoadjuvant chemotherapy. Two of these patients developed recurrences and one died due to progressive disease at 49 months. All neonates were healthy and had no abnormalities. In conclusion, neoadjuvant chemotherapy with paclitaxel and platinum followed by radical surgery may be an option for pregnant women with invasive cervical cancer.
迄今为止,仅有 7 例妊娠期 Ib1 至 IIb 期宫颈癌患者接受新辅助化疗后行根治性手术治疗的报道。我们描述了 3 例妊娠期 Ib1 至 IIa 期宫颈癌患者接受紫杉醇联合铂类新辅助化疗后行根治性手术治疗的情况。第 1 例患者为宫颈小细胞神经内分泌癌 Ib1 期,第 2 例为宫颈 8cm 鳞癌 IIa 期,第 3 例为 Ib2 期鳞癌且淋巴结阳性。对这 3 例患者及其新生儿进行了随访。所有患者对新辅助化疗均有部分或完全缓解。其中 2 例患者复发,1 例患者因疾病进展于 49 个月时死亡。所有新生儿均健康,无异常。总之,紫杉醇联合铂类新辅助化疗后行根治性手术可能是妊娠期浸润性宫颈癌患者的一种选择。